Edition:
India

Edwards Lifesciences Corp (EW.N)

EW.N on New York Stock Exchange

195.25USD
12:29am IST
Change (% chg)

$1.24 (+0.64%)
Prev Close
$194.01
Open
$194.17
Day's High
$195.79
Day's Low
$193.17
Volume
90,552
Avg. Vol
356,486
52-wk High
$197.30
52-wk Low
$134.53

Latest Key Developments (Source: Significant Developments)

Edwards Comments On Updated Tavr National Coverage Determination
Saturday, 22 Jun 2019 

June 21 (Reuters) - Edwards Lifesciences Corp ::EDWARDS COMMENTS ON UPDATED TAVR NATIONAL COVERAGE DETERMINATION.EDWARDS LIFESCIENCES CORP - COMPANY IS NOT UPDATING OR CHANGING ITS FINANCIAL GUIDANCE.  Full Article

Neovasc Resolves Three Claims For Correction Of Patent Inventorship Made By Edwards Lifesciences CardiAQ LLC
Thursday, 18 Apr 2019 

April 17 (Reuters) - Neovasc Inc ::NEOVASC ANNOUNCES RESOLUTION OF LAST REMAINING ACTIVE LITIGATION.NEOVASC - HAS RESOLVED THREE CLAIMS FOR CORRECTION OF PATENT INVENTORSHIP MADE BY EDWARDS LIFESCIENCES CARDIAQ LLC IN U.S. COURT.  Full Article

Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement
Tuesday, 15 Jan 2019 

Jan 15 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC, EDWARDS LIFESCIENCES AGREE TO GLOBAL LITIGATION SETTLEMENT.BOSTON SCIENTIFIC CORP - ALL PATENT LITIGATION BETWEEN COMPANIES TO BE DISMISSED.BOSTON SCIENTIFIC CORP - EDWARDS HAS MADE A ONE-TIME PAYMENT TO BOSTON SCIENTIFIC OF $180 MILLION.BOSTON SCIENTIFIC CORP - ANY INJUNCTIONS CURRENTLY IN PLACE WILL BE LIFTED.BOSTON SCIENTIFIC CORP - NO FURTHER ROYALTIES WILL BE OWED BY EITHER PARTY UNDER AGREEMENT.BOSTON SCIENTIFIC CORP - CO & EDWARDS TO SETTLE ALL OUTSTANDING PATENT DISPUTES BETWEEN THEM.  Full Article

Edwards' Sapien 3 Ultra Transcatheter Heart Valve Receives FDA Approval
Friday, 28 Dec 2018 

Dec 28 (Reuters) - Edwards Lifesciences Corp ::EDWARDS' SAPIEN 3 ULTRA TRANSCATHETER HEART VALVE RECEIVES FDA APPROVAL.  Full Article

Edwards Lifesciences Corp - Sees 2018 Adjusted Sales At Higher End Of $3.5-3.9 Billion
Wednesday, 5 Dec 2018 

Edwards Lifesciences Corp ::EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY AT ANNUAL INVESTOR CONFERENCE.REAFFIRMING OCTOBER 2018 FINANCIAL GUIDANCE.PROJECTED 2019 GLOBAL SALES $3.9-4.3 BILLION.ESTIMATED 2019 ADJUSTED EARNINGS PER SHARE $5.05-5.30.FOCUSED LONG-TERM GROWTH INVESTMENTS WITH 2019 RESEARCH AND DEVELOPMENT PLANNED AT 17-18% OF SALES.SEES 2019 UNDERLYING SALES GROWTH 9-12%.PROJECTED 2019 TAVR SALES $2.4-2.7 BILLION; UNDERLYING GROWTH 11-15%.FAVORABLE PARTNER 3 TRIAL RESULTS EXPECTED IN MARCH; COMMERCIAL APPROVAL IN LATE 2019.SEES FY 2019 FREE CASH FLOW $800-900 MILLION.EXPECTS TO LAUNCH KONECT SYSTEM IN 2019 IN BOTH U.S. AND EUROPE.FY2018 EARNINGS PER SHARE VIEW $4.70, REVENUE VIEW $3.81 BILLION -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $5.20, REVENUE VIEW $4.17 BILLION -- REFINITIV IBES DATA.SEES 2018 ADJUSTED EPS $4.60-$4.75.SEES 2018 ADJUSTED SALES AT HIGHER END OF $3.5-3.9 BILLION.SEES 2018 ADJUSTED FREE CASH FLOW HIGHER END $700-775 MILLION.  Full Article

Edwards Lifesciences Says Reports Qtrly Adjusted Earnings Per Share $1.07
Wednesday, 24 Oct 2018 

Oct 23 (Reuters) - Edwards Lifesciences Corp ::EDWARDS LIFESCIENCES - QTRLY EARNINGS PER SHARE $1.06; QTRLY ADJUSTED EARNINGS PER SHARE $1.07; QTRLY SALES $907 MILLION, UP 10 PERCENT.EDWARDS LIFESCIENCES - QTRLY ADJUSTED. SALES $921 MILLION, UP 11 PERCENT.EDWARDS LIFESCIENCES - RECONFIRMED 2018 TOTAL COMPANY ADJUSTED SALES AND EPS GUIDANCE RANGES.EDWARDS LIFESCIENCES - QTRLY THVT SALES $558 MILLION, UP 16 PERCENT; UP 13 PERCENT ON AN UNDERLYING BASIS.EDWARDS LIFESCIENCES - REMAINS ON TRACK TO RECEIVE CE MARK OF SAPIEN 3 ULTRA SYSTEM IN Q4.EDWARDS LIFESCIENCES - Q3 CARDIOBAND SYSTEM SALES, INCLUDED IN THVT, WERE LIMITED DUE TO ONGOING SUPPLY CONSTRAINT THAT IS EXPECTED TO CONTINUE IN Q4.EDWARDS LIFESCIENCES SEES Q4 ADJUSTED. SALES TO BE BETWEEN $950 MILLION AND $1 BILLION; SEES Q4 ADJUSTED. EARNINGS PER SHARE OF $1.05 TO $1.20.Q3 EARNINGS PER SHARE VIEW $1.02, REVENUE VIEW $928.2 MILLION -- THOMSON REUTERS I/B/E/S.Q4 EARNINGS PER SHARE VIEW $1.21, REVENUE VIEW $995.4 MILLION -- THOMSON REUTERS I/B/E/S.FY2018 EARNINGS PER SHARE VIEW $4.68, REVENUE VIEW $3.83 BILLION -- THOMSON REUTERS I/B/E/S.EDWARDS LIFESCIENCES - Q4 THVT UNDERLYING SALES GUIDANCE MODERATED; CRITICAL CARE GUIDANCE RAISED.  Full Article

Edwards Lifesciences Corp Comments On German Court Decision
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - Edwards Lifesciences Corp ::EDWARDS COMMENTS ON GERMAN COURT DECISION.EDWARDS LIFESCIENCES- DISTRICT COURT IN GERMANY, GRANTED BOSTON SCIENTIFIC'S REQUEST FOR A PRELIMINARY INJUNCTION ON FUTURE COMMERCIAL SALES.EDWARDS LIFESCIENCES CORP - INJUNCTION WILL ONLY BECOME EFFECTIVE IF BOSTON SCIENTIFIC ENFORCES IT AND PROVIDES A BOND OF EUR 10 MILLION.EDWARDS LIFESCIENCES-SAPIEN 3 ULTRA VALVE NOT YET APPROVED FOR COMMERCIAL SALE & SUBJECT OF CLINICAL STUDY FOR EUROPEAN APPROVAL, WHICH WILL CONTINUE.EDWARDS LIFESCIENCES CORP - COOURT'S DECISION HAS NO EFFECT ON SALES OF CO'S SAPIEN 3 OR CENTERA VALVES.  Full Article

Boston Scientific Prevails In German Edwards Lifesciences Litigation
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - Boston Scientific Corp ::BOSTON SCIENTIFIC PREVAILS IN GERMAN EDWARDS LIFESCIENCES LITIGATION.BOSTON SCIENTIFIC - COURT RULES EDWARDS LIFESCIENCES' NEXT-GENERATION VALVE INFRINGES CO'S PATENT, GRANTS RIGHT TO ENJOIN SALES IN GERMANY.BOSTON SCIENTIFIC CORP - ANTICIPATES LOTUS EDGE VALVE SYSTEM WILL BE COMMERCIALIZED IN CE MARK COUNTRIES IN Q1 2019.BOSTON SCIENTIFIC - DISTRICT COURT OF DUSSELDORF DETERMINED THAT EDWARDS LIFESCIENCES CORPORATION'S SAPIEN 3 ULTRA DEVICE INFRINGED A PATENT.BOSTON SCIENTIFIC CORP - ANTICIPATES LOTUS EDGE VALVE SYSTEM WILL GET FDA APPROVAL TO BE SECURED IN MID-2019.  Full Article

Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards Sapien 3 Valve
Tuesday, 22 May 2018 

May 22 (Reuters) - Edwards Lifesciences Corp ::REAL-WORLD EVIDENCE CONFIRMS CLINICAL TRIAL OUTCOMES FOR PATIENTS TREATED WITH EDWARDS SAPIEN 3 VALVE.EDWARDS LIFESCIENCES - EDWARDS SAPIEN 3 VALVE DATA DEMONSTRATED CONSISTENCY WITH THOSE RESULTS ACHIEVED IN EARLIER CONTROLLED CLINICAL TRIALS.  Full Article

Edwards Completes Enrollment In Partner 3 Low-Risk CT Sub-Study
Thursday, 22 Mar 2018 

March 21 (Reuters) - Edwards Lifesciences Corp ::EDWARDS COMPLETES ENROLLMENT IN PARTNER 3 LOW-RISK CT SUB-STUDY, UPDATES TIMELINE FOR SAPIEN 3 ULTRA SYSTEM LAUNCH IN EUROPE.EDWARDS LIFESCIENCES - NOW EXPECTS THAT EUROPEAN LAUNCH OF SAPIEN 3 ULTRA SYSTEM WILL OCCUR LATER IN 2018.EDWARDS LIFESCIENCES - UPDATED TIMING FOR EUROPEAN LAUNCH OF SAPIEN 3 ULTRA SYSTEM DOES NOT CHANGE SALES GUIDANCE FOR 2018.EDWARDS LIFESCIENCES CORP - EDWARDS CONTINUES TO EXPECT U.S. INTRODUCTION OF SAPIEN 3 ULTRA SYSTEM IN LATE 2018.  Full Article

FDA ties three deaths to Edwards Lifesciences' recalled heart devices

The U.S. Food and Drug Administration said on Monday three deaths had been reported related to Edwards Lifesciences Corp's recall of some of its heart devices.